Navigation Links
Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
Date:7/29/2009

DALLAS, July 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that it is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy, and previously announced data suggest that the market for MuGard is significantly greater than previously expected. Frank Jacobucci, formerly President & CEO of Milestone Biosciences, has joined Access as a consultant, and will assist with ongoing reimbursement, manufacturing and commercial launch activities at Access, while discussions with potential licensee and co-promotion partners is ongoing.

"Access is focused on maximizing the potential of MuGard, both for patients and for its shareholders," states Jeffrey B. Davis, Access' President & CEO. "Bringing MuGard back in-house will enable Access to capture more of MuGard's value for shareholders, and be more intimately involved in the ongoing commercialization activities. I welcome the expert insight and experience of Frank Jacobucci, who brings great knowledge and expertise in launching pharma products, with a particular expertise in oral mucositis and related indications, and of course MuGard."

Mr. Jacobucci has over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.

"I have always known the substantial potential for MuGard in the prevention and treatment of oral mucositis as well as it being very important for the medical community, and an exciting commercial opportunity in the pharma sector," stated Frank Jacobucci. "I look forward to working with the Access team while preparing for a MuGard launch in North America and bringing additional pharma resources to bear as needed. These efforts will not only maximize the potential for MuGard but, more importantly, provide access and availability for patients; thus improving outcomes I continue to believe that MuGard is a very important product for the cancer community, as the negative impact of oral mucositis on patient health and treatment is very significant."

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion world-wide.

MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

The previously announced licensing agreement between Access and Milestone Biosciences, LLC for North American rights to MuGard has been terminated.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

    Contact: Company                             Contact: Investor Relations
    Stephen B. Thompson,         Donald C. Weinberger/ Diana Bittner (media)
    Vice President,                      Wolfe Axelrod Weinberger Assoc. LLC
    Chief Financial Officer                                   (212) 370-4500
    Access Pharmaceuticals, Inc.,
    (214)  905-5100


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents
2. Fingertip Formulary Accounts(R) Now Offers Access to Comprehensive Real-Time Account Information and Integrated Formulary Data, in a State-of-the Art Web-Based Platform
3. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
4. Cold Laser Technology Made Even More Accessible with Powerful New Product Available from Laser-Therapy.US
5. Accuray Announces CyberKnife Access Remote Service Product
6. President Obama Announces Intention to Sign United Nations Convention on the Rights of Persons with Disabilities, Impacts Accessible ICT
7. Cost-Conscious Texans Find Relief with Direct Access Lab Testing
8. UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
9. Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
10. Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference
11. Carefx Implements Fusionfx at Fletcher Allen Health Care to Improve Anywhere/Anytime Access to Crucial Patient Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... ... ChenMed , a leading provider of value-based care for seniors, today ... Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine at ... Services for the UVA Health System, brings 30 years of highly relevant experience to ...
(Date:7/20/2017)... NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and application ... arm of one of world’s largest healthcare services providers. , According to ...
(Date:7/20/2017)... ... 20, 2017 , ... For individuals with extended hospital stays or who are ... such facilities are specially designed to accommodate patients with a wide range of ailments ... from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed armrest ...
(Date:7/20/2017)... ... , ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission ... teaming up with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One ... “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and ...
(Date:7/20/2017)... Annapolis, MD (PRWEB) , ... July 20, 2017 ... ... Maryland company dedicated to the development of non-invasive devices and systems for monitoring ... $1.5 million. , Proceeds will be used to complete regulatory submissions and fund ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... to resolve pending patent litigation in the U.S. District Court ... regarding the Cialis ® (tadalafil) unit dose patent. This ... As part of the agreement, Cialis exclusivity is now expected ... "The unit dose patent for Cialis is valid and ...
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
Breaking Medicine Technology: